According to the guidelines of the European Association for the Study of Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clínic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in 5 stages (0, A, B, C and D) on the basis of a number of prognostic and treatment-related variables such as tumor status and liver function. A specific treatment approach is then proposed for each of the above-mentioned stages.
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
MARCEGLIA, SARA RENATA FRANCESCA;
2015-01-01
Abstract
According to the guidelines of the European Association for the Study of Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clínic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in 5 stages (0, A, B, C and D) on the basis of a number of prognostic and treatment-related variables such as tumor status and liver function. A specific treatment approach is then proposed for each of the above-mentioned stages.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2846032.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Digital Rights Management non definito
Dimensione
2.56 MB
Formato
Adobe PDF
|
2.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
